Expanded Access of Prochymal (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) Infusion for the Treatment of Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD

Trial Profile

Expanded Access of Prochymal (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) Infusion for the Treatment of Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD

Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 14 Nov 2016

At a glance

  • Drugs Remestemcel-L (Primary)
  • Indications Graft-versus-host disease
  • Focus Therapeutic Use
  • Sponsors Mesoblast
  • Most Recent Events

    • 14 Nov 2016 Results published in a Mesoblast Limited media release.
    • 25 Aug 2016 Data from this trial (n=241) presented at the tandem annual scientific meetings of the Center for International Blood & Marrow Transplant Research, the American Society of Blood and Marrow Transplantation and at the third International Conference on Regenerative Medicine.
    • 16 Feb 2015 Interim results published in the Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top